Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HypoCat is a veterinary vaccine designed to neutralize the major cat allergen, Fel d 1, within the cat itself to reduce allergic reactions in humans. Developed by Saiba Animal Health, the vaccine utilizes a virus-like particle (VLP) platform derived from the cucumber mosaic virus (CuMV-tt) which is coupled with the recombinant Fel d 1 protein. Upon subcutaneous administration, the vaccine induces the cat's immune system to produce specific neutralizing antibodies against its own Fel d 1 protein. These antibodies bind to the allergen in the cat's secretions, such as saliva and lacrimal fluid, significantly reducing the amount of active Fel d 1 shed into the environment. This innovative approach aims to alleviate symptoms for cat-allergic individuals without requiring them to take medication or rehome their pets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HypoCat.